Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Children With Moderately to Severely Active Crohn's Disease
NCT07298421Phase 3Recruiting
- Sponsor
- Roche
- Start
- Aug 2026
- Primary completion
- May 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of afimkibart in Crohn's disease (2 arms), sponsored by Roche. Primary endpoints: Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI) at 52 weeks and Endoscopic Response at 52 weeks. Started Aug 2026; status: recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07298421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298421.